EGFR and liver cancer: It is a cytoplasmic protein that binds to the kinase domain of EGFR and ERBB2, locking it into a catalytically inactive conformation, thus resulting in the signal attenuation of EGFR signaling5.The expression of Mig-6 has been demonstrated to be suppressed in liver cancer tissues, leading to increased EGFR-AKT signaling and enhanced cell migration6.